Genomma Lab
Genomma Lab Names Rodrigo Herrera Aspra Interim Chief Executive Officer
Genomma Lab announced a leadership change on September 17, 2026. Genomma Lab appointed founder and Chairman Rodrigo Herrera Aspra interim CEO effective January 1, 2027, with a mandate to fully implement a new operating model supported by a platform of AI agents, while Juan Marco Sparvieri remains engaged in the transition through December 31, 2026.
What changed
Rodrigo Herrera Aspra was named Interim Chief Executive Officer. Juan Marco Sparvieri will continue to lead the company through the third quarter and remain actively engaged in the transition through December 31, 2026, the company said.
- Leader: Rodrigo Herrera Aspra
- Role: Interim Chief Executive Officer
- Effective: January 1, 2027
- Announcement date: September 17, 2026
Leadership background
Herrera is the founder and Chairman of the Board of Genomma Lab and will continue to serve as Chairman while serving as interim CEO. Board member Joaquin Ley said Herrera founded the company with an innovative approach to building consumer health brands and that innovation has remained at the core of his leadership for nearly three decades.
The mandate
Genomma Lab said Herrera is expected to serve as interim CEO for a 12 to 18-month period with a mandate to fully implement a new operating model, under which each launch is built around a single creative idea and the model is supported by a platform of AI agents. The company said it will also add brands, products and technologies from partner companies using that platform, and that the Board will search for a successor to Herrera during this period.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Genomma Lab leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started